Cinacalcet drug monograph
WebPregnancy. Limited case reports of use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes; in animal reproduction studies, when female rats were exposed to the drug during the period of organogenesis through to weaning at 2-3 times systemic drug levels (based on AUC) at maximum recommended … WebCinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe. It is used to treat hyperparathyroidism due to parathyroid tumours or renal failure. Type Small Molecule Groups Approved Structure Similar Structures Weight Average: 357.412 Monoisotopic: 357.170434324 Chemical …
Cinacalcet drug monograph
Did you know?
WebSENSIPAR Product Monograph Page 4 of 26 CONTRAINDICATIONS SENSIPAR (cinacalcet hydrochloride) is contraindicated in patients with hypersensitivity to any of the components of this product. SENSIPAR (cinacalcet hydrochloride) should not be initiated in patients with a serum calcium (corrected for albumin) below the lower limit of the normal … WebAug 12, 2024 · Sensipar ( cinacalcet) is a calcimimetic agent that decreases levels of parathyroid hormone (PTH), calcium, and phosphorous in the body used to treat hyperparathyroidism (overactive parathyroid glands) in people who are on long-term dialysis for kidney disease.
Web2 3-Tier Tier 1: Generics Generic medications are effective, low-cost alternatives to brand-name medications. They’re expected to work the same as brand- Webpms-CINACALCET – Product Monograph Page 3 of 28 Prpms-CINACALCET (cinacalcet tablets) PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY PRODUCT INFORMATION Route of Administration Dosage Form/Strength All Nonmedicinal Ingredients Oral
WebCINACALCET/Sensipar (sin a CAL set) is used to treat patients with chronic kidney disease who are on dialysis. It is also used to treat high levels of calcium in the blood of patients with certain parathyroid gland problems. Pricing Drug Information Drug Interactions Images Videos Lifestyle Interactions Monographs Monographs-Pediatrics WebCINACALCET/Sensipar (sin a CAL set) treats an overactive parathyroid gland (hyperparathyroidism) in people with kidney disease. It works by lowering parathyroid …
WebIndications and Dosage. Adult: Initially, 30 mg bid, titrated every 2-4 weeks through sequential doses of 30 mg bid, 60 mg bid, 90 mg bid, and 90 mg 3 or 4 times daily as needed to normalise the serum Ca levels. Adult: Alone or in combination with phosphate binders and/or vitamin D sterols: Initially, 30 mg once daily, may titrate dose in ...
WebAPO-CINACALCET controls parathyroid hormone levels, calcium and phosphorous levels, and the serum calcium-phosphorous product (Ca x P), in patients with CKD receiving … house door seal weatherstrippingWebDrug Monographs Cinacalcet. Basics. Name. Cinacalcet. Pronunciation (sin a KAL cet) Brand Names: US. Sensipar; Therapeutic Category. Calcimimetic; Generic Availability … lintott quilt booksWebView cinacalcet drug monograph Navigate to section Tablet Granules There can be variation in the licensing of different medicines containing the same drug. Tablet All products Show Cautionary and advisory labels Show Cinacalcet 30mg tablets A A H Pharmaceuticals Ltd Show Cinacalcet 30mg tablets Accord Healthcare Ltd Show lintot pub southwaterWebFeb 9, 2024 · Cinacalcet was started at ≤0.2 mg/kg/day in 22 patients (mean age: 13.3 ± 3.6 years) and titrated every 4 weeks to goal iPTH. For the efficacy endpoint phase, the … lintott constructionWebdrugs are exactly the same as the active ingredients in brand drugs whose patents have expired. They are required by the Food and Drug Administration (FDA) to be as safe and … house down road shana boyerWebThis book is based on The complete German Commission E monographs - Therapeutic guide to herbal medicines (published in 1998). The original book detailed 380 … house down the blockWebAPO-CINACALCET Product Monograph Page 1 of 25 PRODUCT MONOGRAPH PrAPO-CINACALCET Cinacalcet Tablets 30 mg, 60 mg and 90 mg ... hydrochloride group and 0.1% in the placebo group permanently discontinued study drug due to hypocalcemia. APO-CINACALCET is not indicated for CKD patients not receiving dialysis. Investigational … lintott architects